Western Drugs Ltd

westerndrugs.com

The Western Drugs Ltd (WDL) is a leading flagship company of Ranka Group. The group is working in various domain including pharmaceuticals. WDL produce and supply Niacin and Niacinamide world wide. WDL have WHO-GMP, ISO 9001:2007, FAMI-QS and HACCP certification. The group turnover is approx USD 100mn.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

FDA STUDY ASKS WHETHER DRUG NAMES CHANGE HOW CONSUMERS, DOCS VIEW MEDS

FiercePharma | January 22, 2020

news image

The FDA wants to know what, exactly, is in a drug name. Specifically, can a brand moniker determine how consumers and healthcare providers perceive the drug? So, the agency has launched a study to determine whether names sway opinions about a drug's effectiveness. Drugmakers submit their proposed names to the FDA for approval, but the companies often hire branding agencies to help create a name. The agency’s job is to make up brand names that draw relevant connections but follow FDA gu...

Read More

Pharma Tech

IKTOS ANNOUNCES DEPLOYMENT OF THEIR AI FOR DRUG DESIGN SOFTWARE MAKYA™ BY JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

Iktos | December 09, 2021

news image

Iktos, a company specialized in Artificial Intelligence for new drug design today announced recent collaboration agreement in AI for new drug design with Jiangsu Hengrui Pharmaceuticals Co., Ltd., a leading global pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Under the agreement, Iktos’ de novo generative design software Makya™ will be used by Hengrui scientists to ...

Read More

Business Insights

HEALTH CANADA APPROVES IPSEN’S SOHONOS™ (PALOVAROTENE CAPSULES) AS THE FIRST APPROVED TREATMENT FOR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA

Ipsen | January 24, 2022

news image

Ipsen announced the Health Canada approval of Sohonos, an oral selective retinoic-acid receptor gamma agonist indicated to reduce the formation of heterotopic ossification in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia ossificans progressiva.1 Sohonos is approved for the treatment of patients with FOP for both chronic use, and for flare-ups, in these patient populations. This decision marks the first approval for Sohonos worldwide.<...

Read More

Pharma Tech

INNOVATION ZED ANNOUNCE 2022 LAUNCH OF INSULCHECK DOSE ADD-ON TECHNOLOGY FOR INSULIN PENS

Zed | November 15, 2021

news image

Innovation Zed, developer of novel diabetes management technologies headquartered at NovaUCD, at University College Dublin, Ireland are delighted to announce today the arrival of the much anticipated InsulCheck DOSE technology that will be coming to market in 2022. "It is with great excitement that we announce the arrival of our InsulCheck DOSE by Innovation Zed. As the third generation product of the InsulCheck family, this technology has been a dream o...

Read More
news image

FDA STUDY ASKS WHETHER DRUG NAMES CHANGE HOW CONSUMERS, DOCS VIEW MEDS

FiercePharma | January 22, 2020

The FDA wants to know what, exactly, is in a drug name. Specifically, can a brand moniker determine how consumers and healthcare providers perceive the drug? So, the agency has launched a study to determine whether names sway opinions about a drug's effectiveness. Drugmakers submit their proposed names to the FDA for approval, but the companies often hire branding agencies to help create a name. The agency’s job is to make up brand names that draw relevant connections but follow FDA gu...

Read More
news image

Pharma Tech

IKTOS ANNOUNCES DEPLOYMENT OF THEIR AI FOR DRUG DESIGN SOFTWARE MAKYA™ BY JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

Iktos | December 09, 2021

Iktos, a company specialized in Artificial Intelligence for new drug design today announced recent collaboration agreement in AI for new drug design with Jiangsu Hengrui Pharmaceuticals Co., Ltd., a leading global pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Under the agreement, Iktos’ de novo generative design software Makya™ will be used by Hengrui scientists to ...

Read More
news image

Business Insights

HEALTH CANADA APPROVES IPSEN’S SOHONOS™ (PALOVAROTENE CAPSULES) AS THE FIRST APPROVED TREATMENT FOR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA

Ipsen | January 24, 2022

Ipsen announced the Health Canada approval of Sohonos, an oral selective retinoic-acid receptor gamma agonist indicated to reduce the formation of heterotopic ossification in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia ossificans progressiva.1 Sohonos is approved for the treatment of patients with FOP for both chronic use, and for flare-ups, in these patient populations. This decision marks the first approval for Sohonos worldwide.<...

Read More
news image

Pharma Tech

INNOVATION ZED ANNOUNCE 2022 LAUNCH OF INSULCHECK DOSE ADD-ON TECHNOLOGY FOR INSULIN PENS

Zed | November 15, 2021

Innovation Zed, developer of novel diabetes management technologies headquartered at NovaUCD, at University College Dublin, Ireland are delighted to announce today the arrival of the much anticipated InsulCheck DOSE technology that will be coming to market in 2022. "It is with great excitement that we announce the arrival of our InsulCheck DOSE by Innovation Zed. As the third generation product of the InsulCheck family, this technology has been a dream o...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us